Trials / Completed
CompletedNCT02323178
A Study of Eltrombopag in Patients With CMML and Thrombocytopenia
A Phase I/II Study of Eltrombopag in Patients With Chronic Myelomonocytic Leukemia and Thrombocytopenia
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Groupe Francophone des Myelodysplasies · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Treatment of patients with chronic myelomonocytic leukemia (CMML) and thrombocytopenia.
Detailed description
All eligible patients will be treated with eltrombopag for a minimum of twelve weeks and a maximum of 24 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | eltrombopag | initial dose of 50 mg once daily, then the dose can be sequentially increased every 2 weeks up to a maximum dose of 300mg/day |
Timeline
- Start date
- 2014-08-07
- Primary completion
- 2018-12-01
- Completion
- 2021-04-01
- First posted
- 2014-12-23
- Last updated
- 2021-04-20
Locations
26 sites across 1 country: France
Source: ClinicalTrials.gov record NCT02323178. Inclusion in this directory is not an endorsement.